Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 4Genitourinary 3Thoracic 2Other hematologic neoplasm 2Gastrointestinal 1

Conditions

Prostatic Neoplasms 2Neoplasms 1Neoplasm Metastasis 1Hormone Refractory Prostate Cancer 1Disease 1

Interventions

pembrolizumab 164Prednisone 130enzalutamide 127Docetaxel 122Abiraterone Acetate 95Nivolumab 93Gemcitabine 71Sunitinib 67atezolizumab 50abiraterone 50Leuprolide 49acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 48Cisplatin 48radium Ra 223 dichloride 39Sorafenib 39darolutamide 38apalutamide 38Ipilimumab 38Carboplatin 37Prednisolone 33Everolimus 33Axitinib 32cabozantinib 31avelumab 31pazopanib 30Bevacizumab 30Paclitaxel 29enfortumab vedotin 28bicalutamide 28Cyclophosphamide 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × gossypol acetic acid × Genitourinary × Clear all
NCT00286793 2011-06-29

Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC

Ascenta Therapeutics

Phase 1/2 Completed
76 enrolled
Genitourinary

Neoplasms, Prostatic Neoplasms

NCT00571675 2010-11-09

A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)

Ascenta Therapeutics

Phase 2 Completed
220 enrolled
Genitourinary

Disease, Neoplasm Metastasis, Prostatic Neoplasms

NCT00286806 2010-08-24

A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer

Ascenta Therapeutics

Phase 1/2 Completed
27 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡